Combined Biomarker and Computed Tomography Screening Strategies for Lung Cancer: Projections of Health and Economic Tradeoffs in the US Population

MDM Policy and Practice

Volumn 1, Issue 1, 2016, Pages

  Kong, Chung Yin ^a,b   Sheehan, Deirdre F ^a   McMahon, Pamela M ^a,b   Gazelle, G Scott ^a,b,c   Pandharipande, Pari ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

biomarker; efficiency frontier; lung cancer; microsimulation; screening

Indexed keywords

EID: 85057808437     PISSN: None     EISSN: 23814683     Source Type: Journal    
DOI: 10.1177/2381468316643968     Document Type: Article

References (22)

1. Moyer VA, ; US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Ann Inter Med. 2014;160(5):330–8. doi:10.7326/M13-2771.
2. Centers for Medicare & Medicaid Services. Decision memo for screening for lung cancer with low dose computed tomography (LDCT) (CAG-00439N); 2015. Available from: http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=274&NcaName=Screening+for+Lung+Cancer+with+Low+Dose+Computed+Tomography+(LDCT)&TimeFrame=7&DocType=All&bc=AQAAIAAAAgAAAA%3d%3d&
3. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. doi:10.1056/NEJMoa1102873.
4. Indovina P, Marcelli E, Pentimalli F, Tanganelli P, Tarro G, Giordano A., Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery. Mass Spectrom Rev. 2013;32(2):129–42. doi:10.1002/mas.21355.
5. Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol. 2008;26(31):5060–6. doi:10.1200/JCO.2008.16.2388.
6. Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2011;22(2):383–9. doi:10.1093/annonc/mdq361.
7. Patz EF, JrCampa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE, 2nd. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol. 2007;25(35):5578–83. doi:10.1200/JCO.2007.13.5392.
8. Hanash SM, Baik CS, Kallioniemi O., Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol. 2011;8(3):142–50. doi:10.1038/nrclinonc.2010.220.
9. McMahon PM, Kong CY, Weinstein MC, et al. Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer. 2008;113(12):3440–9. doi:10.1002/cncr.23962.
10. McMahon PM, Kong CY, Johnson BE, et al. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology. 2008;248(1):278–87. doi:10.1148/radiol.2481071446.
11. McMahon PM, Kong CY, Johnson BE, et al. Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal. 2012;32(Suppl. 1):S117–24. doi:10.1111/j.1539-6924.2011.01652.x.
12. McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol. 2011;6(11):1841–8. doi:10.1097/JTO. 0b013e31822e59b3.
13. Moolgavkar SH, Holford TR, Levy DT, et al. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975–2000. J Natl Cancer Inst. 2012;104(7):541–8. doi:10.1093/jnci/djs136.
14. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the US Preventive Services Task Force. Ann Intern Med. 2014;160(5):311–20. doi:10.7326/m13-2316.
15. McMahon PM, Meza R, Plevritis SK, et al. Comparing benefits from many possible computed tomography lung cancer screening programs: extrapolating from the National Lung Screening Trial using comparative modeling. PLoS One. 2014;9(6):e99978. doi:10.1371/journal.pone.0099978.
16. Meza R, ten Haaf K, Kong CY, et al. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer. 2014;120(11):1713–24. doi:10.1002/cncr.28623.
17. Obuchowski NA., Receiver operating characteristic curves and their use in radiology. Radiology. 2003;229(1):3–8. doi:10.1148/radiol.2291010898.
18. Coate LE, John T, Tsao MS, Shepherd FA., Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol. 2009;10(10):1001–10. doi:10.1016/s1470-2045(09) 70155-x.
19. Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP., The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res (Phila). 2012;5(8):992–1006. doi:10.1158/1940-6207.capr-11-0441.
20. Mandelblatt JS, Cronin KA, Bailey S, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738–47. doi:10.7326/0003-4819-151-10-200911170-00010.
21. Meza R, Meernik C, Jeon J, Cote M., Lung cancer incidence trends by gender, race and histology in the United States, 1973–2010. PLoS One. 2015;10(3):e0121323. doi:10.1371/journal.pone.0121323.
22. Zeliadt SB, Heffner JL, Sayre G, et al. Attitudes and perceptions about smoking cessation in the context of lung cancer screening. JAMA Intern Med. 2015;175(9):1530–7. doi:10.1001/jamainternmed.2015.3558.